Physician profile
Malek M Maatouk
NPI 1972574986
$4,407.95
in general payments reported to CMS, 2019-2025
33 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $188 · 2021: $27.83 · 2022: $428 · 2023: $766 · 2024: $1,379 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $806.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $515.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $413.87 | 2020-2025 | |
| Lilly USA, LLC | $388.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $332.00 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.24 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $209.83 | 2023-2024 | Rexulti, Nuedexta |
| Radius Health, INC. | $162.03 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $129.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $104.92 | 2019-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $102.28 | 2023-2024 | Eliquis |
| Astellas Pharma US INC | $100.52 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $84.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $78.22 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $74.33 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $69.54 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.80 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.12 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $63.18 | 2024 | Voquezna |
| Boston Scientific Corporation | $49.68 | 2025 | Watchman Flx |
| Dexcom, INC. | $48.79 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $48.14 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $46.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.58 | 2019 | |
| Amgen INC. | $34.27 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $26.04 | 2019 | |
| Antares Pharma, INC. | $21.37 | 2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $18.00 | 2023 | Gvoke Hypopen |
| Neurelis, INC. | $15.03 | 2025 | Valtoco |
| Allergan, INC. | $14.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.04 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.89 | 2025 | |
| Circassia INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malek Maatouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.